When most people think of billionaires, they think of people involved in finance, technology or real estate investments. The names of Donald Trump and Bill Gates are often some of the first that come to mind when recognizing the exclusive billionaire club. Builtinchicago.com mentions that Eric Lefkofsky is a name that many probably don’t know as a household name, however, many of his business creations are.
Eric Lefkofsky studied at the University of Michigan, where he eventually earned a Juris Doctor degree. However, his career post law school has not steered him into the courtroom. Instead, Lefkofsky is described as a business entrepreneur. He creates companies and runs them to be highly successful before moving on to the next great business need.
One such company is Tempus. It is a technology company that facilitates Doctors to give a more personalized experience to cancer patients. Tempus does this through its operating system that is not only interactive and analytical to Oncologists but also has the ability to learn. This gives Doctors the necessary tools to provide real-time, highly accurate data-driven decisions for their cancer patients.
More specifically, a patient will provide their Doctor and Tempus blood and tissue samples. Once received at a Tempus lab, the samples are examined for DNA and RNA sequencing. Within two weeks of receiving the samples Tempus researchers are able to identify gene mutations related to that patient’s cancer. Tempus then sends a report to the patient’s Doctor that includes the patient’s specific gene mutations. Obviously, this information alone allows the Doctor to formulate a plan tailored to their patient. However, Tempus goes one step further and includes in the report information from scientific manuals and relevant clinical trials.
So successful has Tempus become that it recently announced a partnership with the prestigious University of Pennsylvania’s Abramskn Cancer Center. Using its proprietary operating system, Tempus provides researchers at the university with sequencing and analysis of pancreatic and melanoma cancer patient tissue samples. This will allow university researchers and physicians to pick the best immunotherapy treatment to give it’s patients at Abramskn.
For Lefkofsky, being a household name billionaire isn’t his main motivation for his pursuits. As can be seen with the revolutionary work being done with Tempus, Lefkofsky is not only an innovator but also a humanitarian.
More information for Eric Lefkofsky: http://finance.yahoo.com/news/eric-lefkofsky-liz-lefkofsky-support-223023277.html